Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche

HOFFMANN-LA ROCHE clinical programs — 58 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

HOFFMANN-LA ROCHE projects

58 ClinicalTrials.gov programs sponsored by HOFFMANN-LA ROCHE.

HOFFMANN-LA ROCHE has 58 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

58 programs

Clinical programs

Page 1 of 2

  1. A Phase I Study of RO7589831 in Participants with Advanced Solid Tumors

    Hoffmann-La Roche

    Advanced solid tumors

    phase 1 other active

    1 trial

  2. Atezolizumab

    Hoffmann-La Roche

    Advanced Ovarian Cancer

    phase 1 small molecule terminated

    1 trial

  3. BN44083

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  4. BO42203

    Hoffmann-La Roche

    Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL), Epstein-Barr virus−positive DLBCL

    phase 1 other active

    1 trial

  5. BO45287

    Hoffmann-La Roche

    Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL)

    phase 1 other active

    1 trial

  6. BP41628

    Hoffmann-La Roche

    Solid Tumors

    phase 1 other active

    1 trial

  7. BP42230

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  8. BP42233

    Hoffmann-La Roche

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  9. BP43015

    Hoffmann-La Roche

    Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  10. BP43131

    Hoffmann-La Roche

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r NHL)

    phase 1 other active

    1 trial

  11. BP44382

    Hoffmann-La Roche

    Small Cell Lung Cancer and Neuroendocrine Carcinoma

    phase 1 other active

    1 trial

  12. BP44551

    Hoffmann-La Roche

    Moderate to Severe Asthma

    phase 1 other active

    1 trial

  13. BP44956

    Hoffmann-La Roche

    Advanced and/or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  14. BP45211

    Hoffmann-La Roche

    Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

  15. BP45228

    Hoffmann-La Roche

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  16. BP45248

    Hoffmann-La Roche

    Not applicable

    phase 1 other active

    1 trial

  17. BP45325

    Hoffmann-La Roche

    Healthy males volunteers

    phase 1 other active

    1 trial

  18. BP45361

    Hoffmann-La Roche

    Parkinson’s Disease

    phase 1 other active

    1 trial

  19. BP45378

    Hoffmann-La Roche

    Huntington’s Disease Gene Expansion Carriers

    phase 1 other active

    1 trial

  20. BP45669

    Hoffmann-La Roche

    Not Applicable (N/A)

    phase 1 other active

    1 trial

  21. BP45670

    Hoffmann-La Roche

    Type 2 Diabetes and obesity

    phase 1 other active

    1 trial

  22. BP45800

    Hoffmann-La Roche

    Obesity or Overweight

    phase 1 other active

    1 trial

  23. BP45801

    Hoffmann-La Roche

    Healthy volunteers

    phase 1 other active

    1 trial

  24. BP45910

    Hoffmann-La Roche

    Healthy Overweight or Obese

    phase 1 other active

    1 trial

  25. BP45932

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  26. BP45980

    Hoffmann-La Roche

    Type 2 Diabetes Mellitus (T2DM) and overweight or obesity

    phase 1 other active

    1 trial

  27. BP46028

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  28. BP46037

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  29. BP46355

    Hoffmann-La Roche

    Stable Coronary Artery Disease (CAD)

    phase 1 other active

    1 trial

  30. BP46585

    Hoffmann-La Roche

    Not Applicable

    phase 1 other active

    1 trial

  31. CO42800

    Hoffmann-La Roche

    Locally Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  32. CO43805

    Hoffmann-La Roche

    Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  33. First-in-Human Study of RO7812653

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)

    phase 1 other active

    1 trial

  34. GA43191

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial

  35. GA46438

    Hoffmann-La Roche

    Active Ulcerative Colitis (UC)

    phase 1 other active

    1 trial

  36. Ipatasertib

    Hoffmann-La Roche

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  37. Midazolam

    Hoffmann-La Roche

    Hepatitis B, Chronic

    phase 1 small molecule completed

    1 trial

  38. Onartuzumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  39. PEG-IFN alfa-2a BA-free formulation (Test)

    Hoffmann-La Roche

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  40. Placebo - MAD

    Hoffmann-La Roche

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  41. RO5323441

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  42. RO5503781

    Hoffmann-La Roche

    Neoplasms

    phase 1 small molecule completed

    1 trial

  43. RO5503781 MBP

    Hoffmann-La Roche

    Myelogenous Leukemia, Acute

    phase 1 small molecule completed

    1 trial

  44. RO7119929

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  45. RO7507062

    Hoffmann-La Roche

    Systemic Lupus Erythematosus

    phase 1 small molecule active

    1 trial

  46. Rugonersen

    Hoffmann-La Roche

    Angelman Syndrome (AS)

    phase 1 small molecule active

    1 trial

  47. Trastuzumab

    Hoffmann-La Roche

    Early Breast Cancer

    phase 1 small molecule completed

    1 trial

  48. WA45032

    Hoffmann-La Roche

    Hepatic Impairment

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does HOFFMANN-LA ROCHE have?

58 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.